Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year ...

J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the company and Janssen had, by failing to obtain a commercial license from Xoma ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...